Elsbernd Brian 4
4 · CATALYST PHARMACEUTICALS, INC. · Filed Sep 5, 2025
Insider Transaction Report
Form 4
Elsbernd Brian
Chief Compliance/Legal Officer
Transactions
- Sale
Common Stock, par value $0.001 per share
2025-09-03$20.08/sh−20,000$401,600→ 188,564 total - Exercise/Conversion
Options to Purchase Common Stock
2025-09-03−20,000→ 989,084 totalExercise: $2.24Exp: 2025-12-19→ Common Stock (20,000 underlying) - Exercise/Conversion
Common Stock, par value $0.001 per share
2025-09-04$2.24/sh+30,000$67,200→ 218,564 total - Sale
Common Stock, par value $0.001 per share
2025-09-04$19.52/sh−30,000$585,600→ 188,564 total - Exercise/Conversion
Common Stock, par value $0.001 per share
2025-09-03$2.24/sh+20,000$44,800→ 208,564 total - Exercise/Conversion
Options to Purchase Common Stock
2025-09-04−30,000→ 959,084 totalExercise: $2.24Exp: 2025-12-19→ Common Stock (30,000 underlying)
Footnotes (4)
- [F1]Shares were sold on the open market for personal reasons and not as a result of a disagreement with the Company.
- [F2]Represents a weighted average price for the shares sold. Shares were sold in a range from $20.035 to $20.13 per share.
- [F3]Represents a weighted average price for the shares sold. Shares were sold in a range from $19.325 to $19.73 per share.
- [F4]Options vested in three annual tranches beginning on December 19, 2019.